Overview
- The provincial health ministry has run maternal RSV vaccination since 2024 and reported 12,819 doses given in 2026 so far, reaching 59.6 percent of the target pregnant population.
- This year Santa Fe used its own funds to buy and begin administering Nirsevimab, a long-acting monoclonal antibody that provides immediate protection for premature newborns who may not receive enough maternal antibodies.
- Health officials held a multi-site training at Hospital de Niños Dr. Orlando Alassia with about 150 clinicians to operationalize the combined prevention strategy across hospitals and primary-care teams.
- Authorities cite early epidemiological signs from the last two winters showing fewer emergency visits and hospitalizations for bronchiolitis, especially in infants under six months, which has lowered pressure on pediatric beds.
- Officials say the next priorities are raising maternal vaccine coverage and ensuring timely access to Nirsevimab for vulnerable newborns, because gaps in timing, prematurity, and incomplete prenatal care still leave some infants at risk.